Price
No data yet.
Social Signal Score
Revenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Richard A. Fair
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 61
- Beta
- 0.24
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 170.98
Financials
Net Income
$-32.48MEBITDA
$-32.48MFree Cash Flow
$-18.63MEPS (diluted)
$-0.49Shares Outstanding (diluted)
66.17M+963.0%Operating Expenses
$37.21MCash & Debt
$895.15MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-103.69M | $-1.83 |
| 2024 | $0.00 | $-89.02M | $-1.89 |
| 2023 | $0.00 | $-71.58M | $-2.01 |
| 2022 | $0.00 | $-37.66M | $-6.03 |
| 2021 | $0.00 | $-24.74M | $-3.17 |
| 2020 | $0.00 | $-18.97M | $-4.31 |
| 2019 | $0.00 | $-23.46M | $-5.43 |
| 2018 | $0.00 | $-11.34M | $-2.62 |
| 2017 | $0.00 | $0.00 | $0.00 |
Valuation
ELVNhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
95Social Signal Score
Mentions (1)
- Newsbenzinga.com·23h ago·Neutral
Enliven's Lead Drug Could Disrupt The Leukemia Treatment Market, Analyst Says Enliven Therapeutics Inc. (NASDAQ:ELVN) drew an Outperform rating from William Blair on Tuesday as the firm initiated coverage, citing the potential for lead drug candidate ELVN-001 to reshape treatment of chronic myeloid leukemia (CML).
View source ↗
Earnings
Wed, Nov 11(in 3 months)
Consensus estimate $-0.43 per share
Typical surprise +7.5% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 5$-0.49 vs $-0.39miss
- Thu, May 7$-0.38 vs $-0.44beat
- Tue, Mar 3$-0.48 vs $-0.42miss
- Wed, Nov 12$-0.32 vs $-0.43beat
- Wed, Aug 13$-0.49 vs $-0.53beat
- Wed, May 14$-0.57 vs $-0.51miss
Estimates and results for ELVN via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ELVN officers and directors.
- Bought
- —
- Sold
- $73.6m
0 trades
54 trades
- Derynck Mika Ksold
- Hohl Benjaminsold
- Hohl Benjaminsold
- Hohl Benjaminsold
- Hohl Benjaminsold
- Hohl Benjaminsold
- Collins Helen Louisesold
- Collins Helen Louisesold
46 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.